A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer

Inclusion Criteria: 1. Subjects has been fully understand this research and volunteered to sign the consent form; 2. Histologically and/or cytologically diagnosed with RAS wild-type metastatic metastatic colorectal cancer(Phase IIIc/IV), any other histological type is excluded; 3. Subjects with stable disease or better after induction treatment with eight to twelve 2-weekly cycles of 5FU-based standard chemotherapy; 4. ECOG Performance Status (ECOG PS) ≤1(0-1); 5. Evident measurable lesion(s) that meets the Response Evaluation Criteria in Solid Tumors (RECIST 1.1); 6. Expected survival\>16 weeks. Exclusion Criteria: 1. Subjects with presence of clinically detectable second primary malignant tumors at the enrollment, or other malignant tumors within the last 5 years (excluding adequately treated skin basal cell carcinoma or carcinoma in situ of cervix); 2. Clinical refractory diseases(including uncontrolled epilepsy),and affect survivor; 3. Central Nervous System (CNS) metastatic disease or prior cerebral metastasis; 4. Researchers think that the subjects exist any clinical or laboratory abnormalities or compliance issues and not suitable to participate in this clinical study.